Atlas market file · Equity · Europe
Pharming Group NVPHARM
- Last close
- 1.13
- Change
- +2.54%
- 96-bar range
- 1 – 1.5895
- As of
- 27 Jul 2026
Pharming Group NV is a listed company listed as PHARM on EURONEXT. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- EURONEXT symbol identity
- Chart rail
- TradingView
- File state
- Public profile
PHARM
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
â–® up candle â–® down candle
Weekly outlook: the last 104 weekly closes (+50.07% over the window).
Source rail: Yahoo Finance chart API (PHARM.AS). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for PHARM. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
PHARM public profile
Listed company. Pharming Group NV is connected to current market context, cited company sources and its retained research file.
Pharming Group NV trades as PHARM on EURONEXT. Pharming Group NV (PHARM) has a latest verified close of 1.13, up 2.54%, dated 27 Jul 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. PHARM stays in the main symbols index until Atlas has enough listing or name evidence for a narrower browse group.
PHARM technical readout
Directional bias down. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-27. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on PHARM
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep PHARM research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
PHARM FAQ
What is Pharming Group NV (PHARM)?Pharming Group NV (PHARM) has a latest verified close of 1.13, up 2.54%, dated 27 Jul 2026. Use this page to check the price chart, company context, source-backed...
Pharming Group NV (PHARM) has a latest verified close of 1.13, up 2.54%, dated 27 Jul 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for PHARM?Pharming Group NV (PHARM) has a latest verified close of 1.13, up 2.54%, dated 27 Jul 2026. It brings the latest available chart, company context, cited sources, risks...
Pharming Group NV (PHARM) has a latest verified close of 1.13, up 2.54%, dated 27 Jul 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. PHARM stays in the main symbols index until Atlas has enough listing or name evidence for a narrower browse group.
How often is the PHARM page updated?The PHARM public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The PHARM public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for PHARM?The PHARM file starts with EURONEXT symbol identity and TradingView EURONEXT:PHARM. The page separates verified market context from company evidence and shows open...
The PHARM file starts with EURONEXT symbol identity and TradingView EURONEXT:PHARM. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on PHARM?Yes. The workstation can open a research path for PHARM from the public symbol record and then pull the available public sources for the fuller report.
Yes. The workstation can open a research path for PHARM from the public symbol record and then pull the available public sources for the fuller report.
Is this PHARM page investment advice?No. The PHARM page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The PHARM page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-07-23. Browse FreedomCore Atlas research notes →